About this resource:
Source: The Cochrane Collaborative
Last Reviewed: March 2019
Workgroups: Vision Workgroup
In this Cochrane systematic review, the Cochrane Collaborative found that anti‐vascular endothelial growth factor (anti‐VEGF) medicines — pegaptanib, ranibizumab and bevacizumab — improve vision and reduce vision loss in people with neovascular age‐related macular degeneration (wet AMD). People treated with anti-VEGF medicines also had improvements in eye structure. In addition, researchers found that participants who took ranibizumab or bevacizumab for at least 1 year had similar vision outcomes. The main difference between treatments was cost (bevacizumab was cheaper), and very few serious side effects occurred.
Objectives related to this resource (1)
Solomon, S. D., Lindsley, K., Vedula, S. S., Krzystolik, M. G., & Hawkins, B. S. (2014). Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Cochrane Database of Systematic Reviews, 2014 (8). DOI: 10.1002/14651858.CD005139.pub4.